RE:RE:RE:RE:RE:RE:RE:RE:Scientific Notation LODU seem to not know much. Same as your name.?
Comparing BD with Qdel and Sona is a muggs game.
So BD only went up 6%. That's because this testing is only a small part of the companies revenue. BD is a huge company. For Sona this is it's first product to make money.
As for comparing BDs test with Qdels and Sonas.
They all use different parameters. The FDA testing specs are loose and wide everyone is maximizing different numbers. If u do not look at all numbers and peer review papers it's an apples to oranges comparison. Tthe professional healthcare will use the tests based on their needs. BDs and Adele test are used not for their accuracy but for their 100% NO False positives. A person tested positive is most likely positive. Nothing more is asked of these tests.
Same as buying a car is a 400 HP car better than a car with 350 Up.
whatdoiknow123 wrote: You really are scraping the bottom of the barrel. You are pushing Viemed who have nothing to do with testing and BD whose test is so inferior to Sona´s that it´s share price has risen the staggering amount of 6% since it was given FDA approval. The market speaks for itself. Sona jumped 122% on Validation and has risen more than double BD´s rise in the last few days with no news whatsover. GIVE UP YOU ARE FLOGGING A DEAD HORSE. Your efforts to short Sona are so obvious that they are truly pathetic. Compare sensitivity, ease of use, absence of a very limiting machine and cost and anyone, even you if you are honest, cannot but see tha vast difference between the 2 products. As I said the market speaks clearly and the market is not impressed with the BD offering while its´response to Sona´s recent progress is somewhat different.